Variant O89 O-Antigen of Is Associated With Group 1 Capsule Loci and Multidrug Resistance.

Susan Harris, Marta J Piotrowska, Robert J Goldstone, Ruby Qi, Geoffrey Foster, Ulrich Dobrindt, Jean-Yves Madec, Charlotte Valat, Francesco V Rao, David G E Smith
Author Information
  1. Susan Harris: Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, United Kingdom.
  2. Marta J Piotrowska: Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, United Kingdom.
  3. Robert J Goldstone: The Francis Crick Institute, London, United Kingdom.
  4. Ruby Qi: Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, United Kingdom.
  5. Geoffrey Foster: Veterinary Services, SAC Consulting, Scotland's Rural College, Inverness, United Kingdom.
  6. Ulrich Dobrindt: Institute of Hygiene, University of Münster, Münster, Germany.
  7. Jean-Yves Madec: Unité Antibiorésistances et Virulences Bactériennes, Anses Laboratoire de Lyon, Université Lyon-1, Lyon, France.
  8. Charlotte Valat: Unité Antibiorésistances et Virulences Bactériennes, Anses Laboratoire de Lyon, Université Lyon-1, Lyon, France.
  9. Francesco V Rao: DC Biosciences Ltd., Dundee, United Kingdom.
  10. David G E Smith: Institute of Biological Chemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, United Kingdom.

Abstract

Bacterial surface polysaccharides play significant roles in fitness and virulence. In Gram-negative bacteria such as , major surface polysaccharides are lipopolysaccharide (LPS) and capsule, representing O- and K-antigens, respectively. There are multiple combinations of O:K types, many of which are well-characterized and can be related to ecotype or pathotype. In this investigation, we have identified a novel O:K permutation resulting through a process of major genome reorganization in a clade of . A multidrug-resistant, extended-spectrum β-lactamase (ESBL)-producing strain - 26561 - represented a prototype of strains combining a locus variant of O89 and group 1 capsular polysaccharide. Specifically, the variant O89 locus in this strain was truncated at , flanked by insertion sequences and located between and and we apply the term O89m for this variant. The prototype lacked colanic acid and O-antigen loci between and with this tandem polysaccharide locus being replaced with a group 1 capsule (G1C) which, rather than being a recognized capsule type, this locus matched to K10 capsule type. A genomic survey identified more than 200 strains which possessed the O89m locus variant with one of a variety of G1C types. Isolates from our collection with the combination of O89m and G1C all displayed a mucoid phenotype and 26561 was unusual in exhibiting a mucoviscous phenotype more recognized as a characteristic among strains. Despite the locus truncation and novel location, all O89m:G1C strains examined showed a ladder pattern typifying smooth LPS and also showed high molecular weight, alcian blue-staining polysaccharide in cellular and/or extra-cellular fractions. Expression of both O-antigen and capsule biosynthesis loci were confirmed in prototype strain 26561 through quantitative proteome analysis. Further exploration of more than 200 strains possessing the O89m:G1C combination identified a very high prevalence of multidrug resistance (MDR) - 85% possessed resistance to three or more antibiotic classes and a high proportion (58%) of these carried ESBL and/or carbapenemase. The increasing isolation of O89m:G1C isolates from extra-intestinal infection sites suggests that these represents an emergent clade of invasive, MDR .

Keywords

References

  1. PLoS One. 2016 Jan 29;11(1):e0147434 [PMID: 26824864]
  2. Front Immunol. 2017 Apr 20;8:452 [PMID: 28473832]
  3. J Commun Dis. 2012 Jun;44(2):71-7 [PMID: 25151751]
  4. Microbiol Mol Biol Rev. 2016 Jun 15;80(3):629-61 [PMID: 27307579]
  5. JAMA Ophthalmol. 2016 Nov 1;134(11):1306-1309 [PMID: 27631542]
  6. J Bacteriol. 2010 Jun;192(12):3144-58 [PMID: 20382770]
  7. J Okla State Med Assoc. 2013 Nov;106(11):435-8 [PMID: 24596985]
  8. J Gen Microbiol. 1991 Aug;137(8):1963-70 [PMID: 1955874]
  9. Infect Immun. 1977 Apr;16(1):26-31 [PMID: 326671]
  10. FEMS Microbiol Lett. 2014 May;354(1):1-9 [PMID: 24617921]
  11. Annu Rev Biochem. 2006;75:39-68 [PMID: 16756484]
  12. EcoSal Plus. 2009 Aug;3(2):null [PMID: 26443756]
  13. Biomacromolecules. 2008 Jul;9(7):1988-96 [PMID: 18547107]
  14. Sci Rep. 2017 Jul 11;7(1):5071 [PMID: 28698568]
  15. J Microbiol Methods. 2015 Jun;113:72-4 [PMID: 25911337]
  16. Bioinformatics. 2014 Jul 15;30(14):2068-9 [PMID: 24642063]
  17. Bioinformatics. 2011 Apr 1;27(7):1009-10 [PMID: 21278367]
  18. PLoS One. 2011;6(7):e21664 [PMID: 21765903]
  19. PLoS Pathog. 2015 Feb 13;11(2):e1004691 [PMID: 25679516]
  20. Adv Appl Microbiol. 2008;65:1-26 [PMID: 19026860]
  21. J Antimicrob Chemother. 2015 Jan;70(1):71-4 [PMID: 25150146]
  22. Microbiology. 2011 Feb;157(Pt 2):419-29 [PMID: 21071493]
  23. Microbiol Spectr. 2016 Feb;4(1):null [PMID: 26999397]
  24. Front Microbiol. 2017 Nov 29;8:2365 [PMID: 29238335]
  25. F1000Res. 2017 Feb 28;6: [PMID: 28344773]
  26. J Antimicrob Chemother. 2012 Nov;67(11):2640-4 [PMID: 22782487]
  27. J Bacteriol. 2008 Oct;190(20):6881-93 [PMID: 18676672]
  28. Microb Genom. 2017 Apr 6;3(4):e000108 [PMID: 28785420]
  29. PLoS One. 2014 Sep 19;9(9):e107812 [PMID: 25237815]
  30. J Clin Microbiol. 2012 Apr;50(4):1355-61 [PMID: 22238442]
  31. Antimicrob Agents Chemother. 2014 Jul;58(7):3895-903 [PMID: 24777092]
  32. Infect Immun. 1996 Sep;64(9):3694-702 [PMID: 8751919]
  33. Mol Cell Proteomics. 2016 Sep;15(9):2890-907 [PMID: 27364158]
  34. J Intern Med. 2006 Jun;259(6):606-14 [PMID: 16704562]
  35. Appl Environ Microbiol. 2009 Jan;75(2):483-92 [PMID: 18997023]
  36. J Bacteriol. 2005 Aug;187(15):5259-66 [PMID: 16030220]
  37. Lancet Infect Dis. 2016 Feb;16(2):161-8 [PMID: 26603172]
  38. Microb Genom. 2016 Aug 25;2(8):e000073 [PMID: 28348868]
  39. J Bacteriol. 2003 Feb;185(3):788-800 [PMID: 12533454]
  40. Microb Genom. 2016 Dec 12;2(12):e000102 [PMID: 28348840]
  41. Mol Microbiol. 1999 Mar;31(5):1307-19 [PMID: 10200953]
  42. Acta Microbiol Hung. 1988;35(3):301-5 [PMID: 3067502]
  43. Bioinformatics. 2000 Oct;16(10):944-5 [PMID: 11120685]
  44. Nat Protoc. 2016 Dec;11(12):2301-2319 [PMID: 27809316]
  45. Bioinformatics. 2013 Apr 15;29(8):1072-5 [PMID: 23422339]
  46. Mol Microbiol. 1997 Oct;26(1):145-61 [PMID: 9383197]
  47. FEMS Microbiol Lett. 2004 Jun 15;235(2):265-71 [PMID: 15183873]
  48. J Bacteriol. 1993 Sep;175(17):5384-94 [PMID: 8366025]
  49. Clin Microbiol Infect. 2012 Mar;18(3):268-81 [PMID: 21793988]
  50. FEMS Microbiol Lett. 2005 May 1;246(1):55-65 [PMID: 15869962]
  51. J Clin Microbiol. 2015 Aug;53(8):2410-26 [PMID: 25972421]
  52. Indian J Med Res. 2011 May;133:541-5 [PMID: 21623041]
  53. Nat Methods. 2016 Sep;13(9):731-40 [PMID: 27348712]
  54. Vet Microbiol. 2013 Mar 23;162(2-4):793-9 [PMID: 23127568]
  55. DNA Res. 2015 Feb;22(1):101-7 [PMID: 25428893]
  56. Mol Microbiol. 1996 Dec;22(5):827-40 [PMID: 8971705]
  57. J Comput Biol. 2012 May;19(5):455-77 [PMID: 22506599]
  58. Appl Microbiol Biotechnol. 2004 Mar;64(1):91-8 [PMID: 14661115]
  59. J Proteome Res. 2018 Jan 5;17(1):325-336 [PMID: 29185342]
  60. Source Code Biol Med. 2014 May 03;9:8 [PMID: 24955109]
  61. Genome Announc. 2018 Mar 8;6(10):null [PMID: 29519827]
  62. J Exp Med. 2004 Mar 1;199(5):697-705 [PMID: 14993253]
  63. Genome Biol. 2015 Dec 29;16:294 [PMID: 26714481]
  64. FEMS Microbiol Lett. 2003 Mar 28;220(2):295-301 [PMID: 12670695]
  65. Mol Microbiol. 1997 Dec;26(5):845-51 [PMID: 9426123]
  66. Glycobiology. 2017 Jul 1;27(7):669-676 [PMID: 28402541]
  67. J Bacteriol. 1983 Apr;154(1):269-77 [PMID: 6187729]
  68. ISME J. 2008 Jun;2(6):615-31 [PMID: 18309357]

Word Cloud

Created with Highcharts 10.0.0capsulelocusstrainsvariant1identifiednovelstrain-26561prototypeO89grouppolysaccharideO89mO-antigenG1CO89m:G1ChighresistanceMDRsurfacepolysaccharidesmajorlipopolysaccharideLPSO:KtypescladeESBLlocirecognizedtype200possessedcombinationphenotypeshowedand/orquantitativemultidrugBacterialplaysignificantrolesfitnessvirulenceGram-negativebacteriarepresentingO-K-antigensrespectivelymultiplecombinationsmanywell-characterizedcanrelatedecotypepathotypeinvestigationpermutationresultingprocessgenomereorganizationmultidrug-resistantextended-spectrumβ-lactamase-producingrepresentedcombiningcapsularSpecificallytruncatedflankedinsertionsequenceslocatedapplytermlackedcolanicacidtandemreplacedrathermatchedK10genomicsurveyonevarietyIsolatescollectiondisplayedmucoidunusualexhibitingmucoviscouscharacteristicamongDespitetruncationlocationexaminedladderpatterntypifyingsmoothalsomolecularweightalcianblue-stainingcellularextra-cellularfractionsExpressionbiosynthesisconfirmedproteomeanalysisexplorationpossessingprevalence85%threeantibioticclassesproportion58%carriedcarbapenemaseincreasingisolationisolatesextra-intestinalinfectionsitessuggestsrepresentsemergentinvasiveVariantO-AntigenAssociatedGroupCapsuleLociMultidrugResistanceEscherichiacoliproteomics

Similar Articles

Cited By